Network NCC. NCCN clinical practice guidelines in oncology. Breast Cancer Version 4. 2022.

Abdulkarim B, Deutsch E. Endothelial-cell apoptosis and tumor response to radiotherapy. Lancet Oncol. 2004;5(1):9.

Article  PubMed  Google Scholar 

Roa W, Zhang X, Guo L, et al. Gold nanoparticles sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle. Nanotechnology. 2009;20(37): 375101.

Article  PubMed  Google Scholar 

Li MY, Liu JQ, Chen DP, et al. Radiotherapy induces cell cycle arrest and cell apoptosis in nasopharyngeal carcinoma via the ATM and Smad pathways. Cancer Biol Ther. 2017;18(9):681–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.

Article  PubMed  Google Scholar 

Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333(22):1456–61.

Article  CAS  PubMed  Google Scholar 

Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: a meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet (London, England). 2011;378(9804):1707–16.

Article  CAS  PubMed  Google Scholar 

He L, Lv Y, Song Y, et al. The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity. Cancer Manag Res. 2019;11:5765–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Society AC. Breast cancer facts & figures 2022–2024. 2022.

Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406(6797):747–52.

Article  CAS  PubMed  Google Scholar 

Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98(19):10869–74.

Article  PubMed  PubMed Central  Google Scholar 

Liu FF, Shi W, Done SJ, et al. Identification of a low-risk luminal a breast cancer cohort that may not benefit from breast radiotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(18):2035–40.

Article  Google Scholar 

Wang J, Luo J, Jin K, et al. Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients. Cancer Med. 2020;9(7):2427–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Boniface J, Szulkin R, Johansson ALV. Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: a swedish national 6-year follow-up of 48 986 women. JAMA Surg. 2021;156(7):628–37.

Article  PubMed  PubMed Central  Google Scholar 

Chu QD, Hsieh MC, Lyons JM, et al. 10-year survival after breast-conserving surgery compared with mastectomy in louisiana women with early-stage breast cancer: a population-based study. J Am Coll Surg. 2021;232(4):607–21.

Article  PubMed  Google Scholar 

Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250–63.

Article  PubMed  Google Scholar 

Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochem Biophys Acta. 2015;1856(1):73–85.

CAS  PubMed  Google Scholar 

Nattenmüller CJ, Kriegsmann M, Sookthai D, et al. Obesity as a risk factor for subtypes of breast cancer: results from a prospective cohort study. BMC Cancer. 2018;18(1):616.

Article  PubMed  PubMed Central  Google Scholar 

Cheng TM. Taiwan’s new national health insurance program: genesis and experience so far. Health Aff (Project Hope). 2003;22(3):61–76.

Article  Google Scholar 

Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol Off J Eur Soc Med Oncol. 2011;22(8):1736–47.

Article  CAS  Google Scholar 

Johnson KS, Conant EF, Soo MS. Molecular subtypes of breast cancer: a review for breast radiologists. J Breast Imaging. 2020;3(1):12–24.

Article  Google Scholar 

von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(15):1796–804.

Article  Google Scholar 

Iwamoto T, Kajiwara Y, Zhu Y, et al. Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer. Chin Clin Oncol. 2020;9(3):27.

Article  PubMed  Google Scholar 

Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11(16):5678–85.

Article  CAS  Google Scholar 

Allott EH, Cohen SM, Geradts J, et al. Performance of three-biomarker immunohistochemistry for intrinsic breast cancer subtyping in the AMBER consortium. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2016;25(3):470–8.

Article  CAS  Google Scholar 

Tavassoli FAS, Stuart J. Pathology of the breast. New York: Elsevier; 1992.

Google Scholar 

Kyndi M, Sørensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(9):1419–26.

Article  CAS  Google Scholar 

Wadasadawala T, Mondal M, Paul SN, et al. Should molecular subtype be recommended as one of the selection criteria for accelerated partial breast irradiation? Preliminary results from an Asian cohort. J Contemp Brachytherapy. 2018;10(1):47–57.

Article  PubMed  PubMed Central  Google Scholar 

Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(14):2373–8.

Article  Google Scholar 

Iwamoto T, Bianchini G, Booser D, et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011;103(3):264–72.

Article  CAS  PubMed  Google Scholar 

He MY, Rancoule C, Rehailia-Blanchard A, et al. Radiotherapy in triple-negative breast cancer: current situation and upcoming strategies. Crit Rev Oncol Hematol. 2018;131:96–101.

Article  PubMed  Google Scholar 

Michmerhuizen AR, Lerner LM, Ward C, et al. Androgen and estrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitization in breast cancer. Br J Cancer. 2022;127(5):927–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Michmerhuizen AR, Lerner LM, Pesch AM, et al. Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. NPJ Breast Cancer. 2022;8(1):31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao N, Li S, Wang Z, et al. NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res. 2009;171(1):9–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilson C, Nicholes K, Bustos D, et al. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget. 2014;5(17):7328–41.

Article  PubMed  PubMed Central  Google Scholar 

Hou J, Zhou Z, Chen X, et al. HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo. Oncotarget. 2016;7(29):45186–98.

Article  PubMed  PubMed Central  Google Scholar 

Ren YQ, Fu F, Han J. MiR-27a modulates radiosensitivity of triple-negative breast cancer (TNBC) cells by targeting CDC27. Med Sci Monit Int Med J Exp Clin Res. 2015;21:1297–303.

CAS  Google Scholar 

Yang F, Zhang W, Shen Y, et al. Identification of dysregulated microRNAs in triple-negative breast cancer (review). Int J Oncol. 2015;46(3):927–32.

Article  CAS  PubMed  Google Scholar 

Steffen AC, Göstring L, Tolmachev V, et al. Differences in radiosensitivity between three HER2 overexpressing cell lines. Eur J Nucl Med Mol Imaging. 2008;35(6):1179–91.

Article  CAS  PubMed  Google Scholar 

Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.

Article  CAS  PubMed  Google Scholar 

Giordano A, Gao H, Anfossi S, et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 2012;11(11):2526–34.